T-Therapeutics Raises $133 Million Series B, Pushing Two TCR Bispecific Programs Toward The Clinic

T-Therapeutics has raised $133 million in an oversubscribed series B financing to move its next-generation T cell engager therapeutics into the clinic for cancer and autoimmune diseases. The company said the capital will help speed its T cell receptor bispecific lead programs forward as it transitions toward becoming a clinical-stage company.

The round was co-led by new investors Advent Life Sciences and British Business Bank. Existing and additional backing came from investors including Johnson & Johnson Innovation, Eli Lilly and Sanofi Ventures.

Where The Money Goes

T-Therapeutics said it will use the proceeds to accelerate two CD3-targeting programs from its OpTiMus platform. TTX-008 is its cancer asset for solid tumors, while TTX-018 is being developed for autoimmune and inflammation disorders.

According to the company, OpTiMus provides fully human TCRs intended to reach intracellular targets that have historically been difficult to drug. That makes the financing more than a balance-sheet event: investors are backing a modality claim that could broaden where bispecific formats can be applied if the first programs generate clinical proof.

The Capital Signal

The financing follows a total of $91 million in series A money after T-Therapeutics closed an extension in November 2025. CEO Theodora Harold said the series B supports two oncology and immunology programs with what she described as pan-indication, blockbuster potential.

The company also said Kirsty Crame is joining as chief development officer. Crame previously served as chief medical officer at Curatis and also held roles at Medigene and Gadeta.

The round lands amid a wider funding backdrop in which U.S. biotechs have still captured most private venture capital. BioSpace cited an October J.P. Morgan report showing U.S. biotechs raised $37.2 billion over the past two years, or 68% of the worldwide total. Outside the U.S., European biopharma companies raised $9.2 billion from 2025 through the third quarter of 2026, just under 17% of all deployed capital, with the U.K. accounting for $3.1 billion across 58 rounds. For T-Therapeutics, that context makes the raise a sign that specialist investors remain willing to fund differentiated immunology and oncology platforms in the U.K. despite a tighter regional capital pool.